Objective
to compare polymer-based zotarolimus-eluting stents with polymer-free biolimus-coated stents in patients at high bleeding risk
Study
prospective, multicentre, non-inferiority randomised trial
Population
patients undergoing PCI classified as being at high bleeding risk
Endpoints
composite of death from cardiac causes, myocardial infarction, or stent thrombosis at 1 year
Conclusion
among patients at high bleeding risk who received 1 month DAPT after PCI, use of polymer-based zotarolimus-eluting stents was noninferior to use of polymer-free drug-coated stents with regard to safety
Windecker et al. N Eng J Med. 2020;382:1208-18
